Which eye drop wins the dry eye battle? a Head-to-Head test

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age: Adults ≥ 18 years. * Diagnosis: Clinical diagnosis of mild to moderate dry eye disease in at least one eye with OSDI ≥ 13 to ≤ 32 at screening. * OSDI ≥ 13 to ≤ 32 at screening. * Objective evidence: NITBUT ≤ 10 seconds in the study eye(s) at screening. * Ocular surface status: CFS ≤ grade 3 (Oxford or NEI scale) in the study eye(s). * Stable medications: Systemic medications that may affect tear film must be stable ≥ 30 days prior to screening and expected to remain stable during the study. * Ability to participate: Able and willing to comply with procedures, attend visits, and provide written informed consent. * Contraception: Women of childbearing potential must agree to use an acceptable method of contraception for the study duration and have a negative pregnancy test at screening. Exclusion Criteria: * Active ocular infection or inflammation unrelated to DED (e.g., bacterial/viral conjunctivitis, active uveitis). * Severe ocular surface disease beyond typical DED (e.g., severe keratitis, Stevens-Johnson syndrome, ocular cicatricial pemphigoid). * Excessive corneal staining: CFS \> grade 3 in the study eye(s). * Recent ocular surgery or procedure: ocular surgery, laser, or punctal occlusion within 6 months prior to screening. * Current or prior use within 6 months before screening of either study drop (Systane PRO PF or Blink Triple Care PF) * Contact lens wear: soft or rigid contact lens use within 7 days prior to baseline, or unwillingness to discontinue lenses for the study; consider extending to 14 days if desired. * Use of topical ophthalmic medications that cannot be discontinued (e.g., topical antibiotics, corticosteroids). * Recent investigational product use: participation in another interventional trial or investigational product use within 30 days prior to screening. * Known hypersensitivity: allergy to any component of Systane PRO PF or Blink Triple Care PF. * Confounding systemic conditions: systemic diseases or medications that, in the investigator's judgment, could significantly affect tear production or ocular surface health (e.g., uncontrolled autoimmune disease, recent initiation/change of systemic medications known to affect tear production within 30 days). * Severe visual impairment in the study eye(s) not attributable to DED that would interfere with assessments. * Pregnancy or breastfeeding. * Investigator discretion: any medical, psychiatric, or social condition that would preclude safe participation or reliable completion of study procedures.